InvestorsHub Logo

marjac

06/27/20 5:05 PM

#283281 RE: caddiedad #283279

That's right, caddie, there is no vacatur without consent by H & R. In order to pass FTC muster, the dollar amount would be H & R's costs and legal fees. I don't know what the appropriate pre-2029 market agreement date would be, as the data providing the basis is proprietary, and uniquely within the hands of Amarin. But the framework is at least theoretically viable. Whether the parties can ultimately execute, only time will tell.

Biobillionair

06/27/20 6:26 PM

#283288 RE: caddiedad #283279

Sorry to interject but Amarin longs must recognize the importance of Amarin suppling API to H&R...a supply deal will significantly undercut what TEVA or Apotex could compete with.

The “supply” carrot is noted in Apotex settlement PR here: https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-patent-litigation-settlement-agreement-apotex

Amarin does not commit to supplying Apotex with icosapent ethyl at any time.



BB